CStone Pharmaceuticals (2616) H1 2024 earnings summary

Executive summary

• Achieved profitability in H1 2024, with net profit between RMB10.8 million and RMB15.7 million, reversing a significant loss in H1 2023, driven by license fee income and stringent cost control.

• Total revenue for H1 2024 was RMB254.2 million, with license fee income offsetting a decline in pharmaceutical product sales.

• Major pipeline and commercial milestones include EU approval for sugemalimab, new strategic partnerships, and multiple regulatory submissions and clinical trial initiations planned for 2024–2025.

• Expanded global presence with regulatory approvals and partnerships in Europe and China.

Financial highlights

• Revenue for H1 2024 was RMB254.2 million, down 2.8% year-over-year; license fee income increased by RMB122.6 million, while product sales declined by RMB128.6 million.

• Net profit was RMB15.7 million (adjusted profit: RMB10.8 million), compared to a loss of RMB209.2 million (adjusted loss: RMB183.0 million) in H1 2023.

• Gross profit rose to RMB172.0 million from RMB153.4 million year-over-year.

• Cash and cash equivalents stood at RMB813.9 million as of June 30, 2024.

• Operating expenses, including R&D, administrative, and selling/marketing, were significantly reduced year-over-year.

Outlook and guidance

• Multiple IND submissions and pivotal trial initiations planned for 2024–2025, including CS5001, CS2009, CS5005, CS5006, CS2011, and CS5007.

• Anticipates UK approval for sugemalimab in H2 2024 and global market launches in early 2025.

• Expects further global partnerships, business development activities, and manufacturing localization approvals.